Wave Life Sciences Starts Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne

 FORWARD-53 is fully enrolled with potentially registrational dystrophin expression data expected in 2024

Previous clinical proof-of-concept data demonstrated highest level of exon skipping ever observed in the clinic and that WVE-N531 was present in myogenic stem cells, which are important for potential muscle regeneration

https://www.biospace.com/article/releases/wave-life-sciences-announces-initiation-of-dosing-in-phase-2-forward-53-trial-of-wve-n531-in-duchenne-muscular-dystrophy/